- Home
- SBRA vs PRAX Comparison
SBRA vs PRAX Comparison
Compare SBRA & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- PRAX
- Stock Information
- Founded
- SBRA 2010
- PRAX 2015
- Country
- SBRA United States
- PRAX United States
- Employees
- SBRA N/A
- PRAX N/A
- Industry
- SBRA Real Estate Investment Trusts
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- SBRA Real Estate
- PRAX Health Care
- Exchange
- SBRA Nasdaq
- PRAX Nasdaq
- Market Cap
- SBRA 4.3B
- PRAX 4.0B
- IPO Year
- SBRA N/A
- PRAX 2020
- Fundamental
- Price
- SBRA $19.44
- PRAX $195.31
- Analyst Decision
- SBRA Hold
- PRAX Strong Buy
- Analyst Count
- SBRA 9
- PRAX 13
- Target Price
- SBRA $20.56
- PRAX $228.69
- AVG Volume (30 Days)
- SBRA 3.2M
- PRAX 936.1K
- Earning Date
- SBRA 11-05-2025
- PRAX 11-05-2025
- Dividend Yield
- SBRA 6.15%
- PRAX N/A
- EPS Growth
- SBRA 78.50
- PRAX N/A
- EPS
- SBRA 0.73
- PRAX N/A
- Revenue
- SBRA $747,056,000.00
- PRAX $7,463,000.00
- Revenue This Year
- SBRA $7.75
- PRAX N/A
- Revenue Next Year
- SBRA $9.04
- PRAX $44.43
- P/E Ratio
- SBRA $26.78
- PRAX N/A
- Revenue Growth
- SBRA 9.34
- PRAX 364.98
- 52 Week Low
- SBRA $15.60
- PRAX $26.70
- 52 Week High
- SBRA $19.97
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- SBRA 66.06
- PRAX 60.26
- Support Level
- SBRA $18.33
- PRAX $181.76
- Resistance Level
- SBRA $18.90
- PRAX $192.70
- Average True Range (ATR)
- SBRA 0.39
- PRAX 15.15
- MACD
- SBRA 0.07
- PRAX -2.71
- Stochastic Oscillator
- SBRA 97.48
- PRAX 89.02
About SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.